Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia.

ABSTRACT:

Background

Levodopa-induced dyskinesias are an often debilitating side effect of levodopa therapy in Parkinson's disease. Although up to 90% of individuals with PD develop this side effect, uniformly effective and well-tolerated antidyskinetic treatment remains a significant unmet need. The pathognomonic loss of striatal dopamine in PD results in dysregulation and disinhibition of striatal CaV1.3 calcium channels, leading to synaptopathology that appears to be involved in levodopa-induced dyskinesias. Although there are clinically available drugs that can inhibit CaV1.3 channels, they are not adequately potent and have only partial and transient impact on levodopa-induced dyskinesias.

Methods

To provide unequivocal target validation, free of pharmacological limitations, we d

SUBMITTER: Steece-Collier K 

PROVIDER: S-EPMC6563183 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature